Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco - 1 Jan 2008

Welton Nicky J, Johnstone Elaine C, David Sean P, Munafò Marcus R

Abstract excerpt

We conducted a cost-effectiveness analysis of genetic testing for smoking cessation, based on data available from the published pharmacogenetic studies of nicotine replacement therapy and bupropion, and a previous cost-effectiveness analysis of smoking cessation treatments. We use multiparameter evidence synthesis methods to combine evidence on cessation by genotype with evidence on cessation irrespective of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost of Illness

Share to Counseling

Share to Dopamine Uptake Inhibitors

Share to Models, Economic

Share to Nicotine

Share to Smoking Cessation

Source

Open in PubMed Open full text

Identifiers

PMID: 18188764
DOI: 10.1080/14622200701767761
PMCID: PMC2257987

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.PMID 18188764Read ↗

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.Semantic proximity Read ↗

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.Semantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?Semantic proximity Read ↗

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Semantic proximity Read ↗

Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials.Semantic proximity Read ↗

No evidence for a major role of polymorphisms during bupropion treatment.Semantic proximity Read ↗

Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.